BOSTON, Aug. 14, 2023 /PRNewswire/ NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced the appointment of. -Today at 08:02 am- MarketScreener
/PRNewswire/ NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today.
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Free Report) was the target of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 188,400 shares, a drop of 20.6% from the May 31st total of 237,400 shares. Based on an average daily trading volume, of 364,300 shares, […]
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Free Report) saw a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 188,400 shares, a drop of 20.6% from the May 31st total of 237,400 shares. Based on an average daily trading volume, of 364,300 shares, the days-to-cover ratio […]